<--- Back to Details
First PageDocument Content
Biotechnology / Biology / Medicine / Recombinant proteins / Specialty drugs / Biosimilar / Drugs / Biopharmaceutical / Trastuzumab / Mylan / Pegfilgrastim / Filgrastim
Date: 2016-07-21 09:25:25
Biotechnology
Biology
Medicine
Recombinant proteins
Specialty drugs
Biosimilar
Drugs
Biopharmaceutical
Trastuzumab
Mylan
Pegfilgrastim
Filgrastim

Press Release Mylan & Biocon Announce Regulatory Submission for Proposed Biosimilar Pegfilgrastim Accepted for Review by European Medicines Agency BENGALURU, India and HERTFORDSHIRE, England/PITTSBURGH, USA, July 21, 20

Add to Reading List

Source URL: www.biocon.com

Download Document from Source Website

File Size: 437,77 KB

Share Document on Facebook

Similar Documents

Biotechnology, BS

Biotechnology, BS "DBEFNJD.BQ  5IF"DBEFNJD.BQTFSWFTBTBTVHHFTUFEDPVSTFTFRVFODFPOMZ4UVEFOUTBSFOPUMJNJUFEUPUIJTQMBOJUJTNFBOUUPCFVTFEBT

DocID: 1xTqy - View Document

PDF Document

DocID: 1wroO - View Document

Building A Better Mousetrap:  Patenting Biotechnology In The European Community

Building A Better Mousetrap: Patenting Biotechnology In The European Community

DocID: 1vr7C - View Document

BIOTECH & PHARMA IN FRANCE KEY FACTS & FIGURES ¾¾ The French biotechnology sector ranks number 3 in Europe with more than 400 companies behind the UK and Germany ¾¾ First producer of medicines in Europe with 220 prod

BIOTECH & PHARMA IN FRANCE KEY FACTS & FIGURES ¾¾ The French biotechnology sector ranks number 3 in Europe with more than 400 companies behind the UK and Germany ¾¾ First producer of medicines in Europe with 220 prod

DocID: 1vq6b - View Document

Biotechnology Consultation Agency Response Letter BNF

Biotechnology Consultation Agency Response Letter BNF

DocID: 1vpUZ - View Document